Metastatic

HER2

HER2 +

**BRS0070**
Phase II
PF-05082566 in Combo w/ AdoRastuzumab-Emtansine or Trastuzumab in HER2+ Breast Cancer
Pll: Sledge

**BRS0033**
Phase II Neratinib in Metastatic HER2 Non-amplified but HER2 Mutant Breast Cancer
Pll: Pegram
Washington University, St. Louis

HER2 -

**BRS0087**
Phase III Capecitabine +/- Tesetaxel vs in HER2-/Hormone Receptor+ /Local Advd /Metastatic Brst Can
Pll: Pegram
Pending

**BRS0050**
Phase II BMN 673 in BRCA1 + BRCA2 Wild-Type Patients w/ Advanced Triple-Neg / HER2-Neg Breast Cancer
Pll: Telli
Stanford

**BRS0080**
Phase II Seribantumab + Fulvestrant in Hormone Receptor+, HER2- Metastatic Breast Cancer
Pll: Massarweh Merrimack Pharmaceuticals

ER +/ PR +,

Pre and Post Menopausal

Germline or Somatic Mutation

Hergulin (+)

≤ 3 lines of prior cytotoxic chemo in part 1;
≤ 1 line of prior cytotoxic chemo in part 2

**BRS0089**
Phase I G1T48 in Women w/ Estrogen Receptor-Positive HER2-Negative Advanced Breast Cancer
Pll: Pegram
Pending

**VAR0166**
Phase Ib/II Avelumab In Combination with Talazoparib In Locally Advanced or Metastatic Solid Tumors
Cohort B
Pll: Telli
Pfizer (Pending)

**KEY**

- Pending
- Open for Enrollment
- Link
- Optional Path
- Trial Posting
- Extension Study
- Immunotherapy
- Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu